Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 754091 alone or with BI 836880 in metastatic anal squamous cell carcinoma
2019-004749-33Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in anal squamous cell carcinoma (SCCA) comparing BI 754091 monotherapy with BI 754091 + BI 836880 combination (2 arms). Primary endpoint: Objective response. Started Mar 2020; status: completed.
02
Drugs
ezabenlimabBI 836880
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2019-004749-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004749-33.